Organization

Mesoblast Limited

About

Mesoblast is a biotechnology company focused on developing and commercializing drugs to treat complex disease resistant to the conventional standard of care and where inflammation plays a central role. Its proprietary technology platform is used for innovative allogeneic cellular medicines. Mesoblast has developed mesenchymal lineage adult stem cells (MLCs) that play vital roles in maintaining tissue health and are found in multiple tissues.

Overview

Founded 2004
Type Public
Location Melbourne, Victoria, Australia

Stock

MESO $2.59 -5.13% $(0.14)

Latest News

Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2022 Sep 06, 2022 Benzinga Upgrades Northcoast Research upgraded the previous rating for Ecolab Inc (NYSE:ECL) from Neutral to Buy. Ecolab earned $1.10 in the second quarter, compared to $1.22...
Mesoblast Reports Financial Results and Operational Highlights for Fiscal Year Ended June 30, 2022 Aug 30, 2022 GlobeNewswire Inc. NEW YORK, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported financial results...
Mesoblast Corporate Update and Financial Results Webcast Aug 30, 2022 GlobeNewswire Inc. NEW YORK, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast...
Appendix 4C Quarterly Activity Report Jul 29, 2022 GlobeNewswire Inc. Mesoblast Operational and Financial Highlights for Quarter Ended June 30, 2022 Mesoblast Operational and Financial Highlights for Quarter Ended June 30, 2022
Rexlemestrocel-L to be Highlighted at Maxim’s Panel on Late-Stage Advancements in Heart Failure Therapeutics and Management Jul 12, 2022 GlobeNewswire Inc. NEW YORK, July 11, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that rexlemestrocel-L,...